KA
XENE icon

Kovack Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Kovack Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,300
Closed -$113K – 515
2018
Q2 		$113K Buy
+12,300
New +$76.4K 0.03% 387

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Kovack Advisors's XENE Position: Q3 2018 in Review

Kovack Advisors sold out of Xenon Pharmaceuticals (XENE) in Q3 2018, closing a stake of 12,300 shares — an estimated $113K sold.

Kovack Advisors first reported a position in XENE in Q2 2018 and held it in 1 quarter. The position peaked at $113K in Q2 2018. 59 funds tracked by Wall St. Rank hold XENE as of Q3 2018.

  • Kovack Advisors reported no remaining Xenon Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Kovack Advisors sold 12,300 Xenon Pharmaceuticals shares in Q3 2018, an estimated $113K.
  • Kovack Advisors first reported a position in Xenon Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Kovack Advisors's Xenon Pharmaceuticals position peaked at $113K in Q2 2018.
  • 59 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2018.

Based on Kovack Advisors's 13F filing for Q3 2018, filed 9 Oct 2018.